Statins may help stabilize the atherosclerotic plaque in acute myocardial infarction. 103 patients who underwent primary angioplasty followed by coronary intravascular ultrasound (IVUS) in the culprit artery and not culprit of infarction were included. Patients received 20 mg of rosuvastatin for two weeks and then 40 mg for 13 months ending up with a new...
ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient
The aim of the study was to show a reduction in LDL cholesterol with the use of monoclonal antibody alirocumab as an adjunct therapy to statins in patients already receiving the maximum tolerated dose of statins. This study randomized 720 patients with hypercholesterolemia and high cardiovascular risk to alirocumab 75 mg subcutaneously every 2 weeks...
GAUSS -2: Evolocumab effective in reducing LDL cholesterol in patients intolerant to statins
Adverse effects of statins are relatively common causing poor adherence to treatment and the need for interruption of about 10-20%.The Evolocumab is a fully human monoclonal antibody that inhibits a protein converting subtilisin/ kexin type 9 (PCSK 9); this is a protein that reduces the liver’s ability to remove LDL cholesterol from theblood.This is a...
LAPLACE 2: Evolocumab effective in reducing LDL associated with statins
There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that inhibits protein converting subtilisin / kexin type 9 (PCSK9) showed lowering LDL cholesterol in phase 2 studies. The objective of this Phase 3 study was to evaluate the safety and efficacy...
Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.
Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite the maximal dose or because of adverse effects. Monoclonal antibody RN316 binds to PCSK9 increasing LDL clearance. This trial randomized 135 patients with an average LDL of 120 mg/dl despite the maximal dose statins to receive 4 different...
IVUS plaque regression with high doses of statins
Original title: Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Reference: Räber L et al. Eur Heart J. 2015 Feb 21;36(8):490-500. The long-term effect of intensive statin therapy on coronary atherosclerosis in patients admitted pursuing an ST segment elevation myocardial infarction is unknown. The aim of this study was...
High doses of statins may reduce the lipid content in severe injury
Original title: Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy. The YELLOW Trial (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy). Reference: Annapoorna S. Kini et al. J Am Coll Cardiol 2013;62:21–9. Multiple studies have shown the benefits of statins in reducing all events, stabilize plaques and improve endothelial function. Coronary intravascular ultrasound (IVUS)...
ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive AMI, and these were carried out in the era before AMI was diagnosed with biomarkers and prior to treatment with coronary angioplasty, use of antithrombotic agents and high intensity statins, and angiotensin-aldosterone system inhibitors. The aim of this...
MITRAL Trial, Results at 5 Years
Repeat mitral valve repair has been associated with increased mortality. Transcatheter mitral valve repair has surged as an alternative for patients treated with mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral for annular calcification (ViMAC). Current data from the VIVID and the MAC Global Registry on 30-day evolution in these 3 scenarios show 7.4%, 11.4% and...
TriClip: Good Outcomes After a 2-Year Follow-up
Severe tricuspid regurgitation (TR) is an underestimated condition in healthcare systems. However, it is more common than believed, especially in individuals over 65 years of age. This condition is linked to hospitalizations due to heart failure, mortality rates, and a progressive decline in quality of life. Surgery to treat TR on its own is complicated,...